Pentatricopeptide repeat domain protein 1 lowers the levels of mitochondrial leucine tRNAs in cells

Oliver Rackham1, Stefan M. K. Davies1, Anne-Marie J. Shearwood1, Kristina L. Hamilton1, James Whelan2 and Aleksandra Filipovska1,*

1Western Australian Institute for Medical Research and Centre for Medical Research, The University of Western Australia, Perth, WA 6000 and 2Australian Research Council Centre of Excellence in Plant Energy Biology, The University of Western Australia, Crawley, WA 6009, Australia

Received February 24, 2009; Revised June 27, 2009; Accepted July 14, 2009

ABSTRACT

Although the basic components and mechanisms of mitochondrial transcription in mammals have been described, the components involved in mRNA processing, translation and stability remain largely unknown. In plants, pentatricopeptide domain RNA-binding proteins regulate the stability, expression and translation of mitochondrial transcripts; therefore, we investigated the role of an uncharacterized mammalian pentatricopeptide domain protein, (PTCD1), in mitochondrial RNA metabolism. We show that PTCD1 is a mitochondrial matrix protein which associates with leucine tRNAs and precursor RNAs that contain leucine tRNAs. Knockdown of PTCD1 in 143B osteosarcoma cells did not change mitochondrial mRNA levels; however, it increased the abundance precursor RNAs and leucine tRNAs and PTCD1 overexpression led to a reduction of these RNAs. Lowering PTCD1 in cells increased levels of several mitochondria-encoded proteins and Complex IV activity, suggesting that PTCD1 acts as a negative regulator of leucine tRNA levels and hence mitochondrial translation.

INTRODUCTION

Human mitochondrial DNA (mtDNA) is a circular double-stranded genome that encodes 22 tRNAs, 2 rRNAs and 13 protein subunits of the electron transport chain complexes (1). Therefore, human mtDNA is dependent on nuclear-encoded proteins for replication, repair, transcription and translation. This dependency lies at the heart of several human diseases that are caused by defects of mtDNA maintenance and expression (2). Human mitochondrial diseases can encompass mutations of both mtDNA and nuclear DNA (3). However, the identification of mtDNA or OXPHOS abnormalities in Parkinson’s disease, Alzheimer’s disease, cancer and diabetes indicate that our understanding of mitochondrial function in disease is still in its infancy (4). The most significant gaps in our knowledge of mitochondrial function and disease are in the regulation of mitochondrial gene expression (5,6). This is particularly important since remarkable tissue-, cell- and disease-specific variations have been observed in the expression of different mitochondrial RNAs, but cannot be explained at present (7–9). Mitochondrial RNAs are transcribed as part of long polycistronic, precursor transcripts that generally encompass the entire mtDNA and are processed by removing interspersed tRNAs to release the individual mRNAs and rRNAs (10). Therefore, large variations in ratios of the 13 levels of individual mRNAs and their proteins must be controlled at a post-transcriptional level. Mitochondrial transcripts are subsequently polyadenylated at their 3’ ends to yield the mature mRNAs, which are translated on mitochondrial ribosomes, while tRNAs and rRNAs are subject to specific nucleotide modifications and CCA is added to the 3’ end of tRNAs (11,12). Little is known about how the levels of specific RNAs are regulated in mammalian mitochondria.

The best-characterized RNA-binding protein known to regulate mammalian mitochondrial gene expression is the leucine-rich pentatricopeptide repeat cassette (LRPPRC) protein (13–15). This was recently identified as a gene causing the rare French–Canadian variant of Leigh syndrome, a debilitating neurodegenerative condition resulting from mitochondrial cytochrome c oxidase deficiency (15). Mutation of the LRPPRC gene results in decreased levels of the cytochrome oxidase (COX) I and III mRNAs (14); however, the RNA sequence that this protein binds has not been identified. LRPPRC is one of the seven mammalian mitochondrial PPR domain proteins, along with the mitochondrial RNA polymerase (POLRMT), mitochondrial ribosomal protein of the small subunit 27 (MRPS27), pentatricopeptide repeat domain proteins (PTCD) 1, 2 and 3 and mitochondrial RNase P protein 3 (MRPP3), which is a recently identified subunit

*To whom correspondence should be addressed. Tel: +61 8 9224 0330; Fax: +61 8 9224 0322; Email: afilipov@waimr.uwa.edu.au

© 2009 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
of the mammalian mitochondrial RNase P complex (16, 17). PPR domain proteins were identified first in plants, where they constitute a large family of mitochondrial and chloroplast proteins involved in transcript processing, editing and translation (18). Recently, the PPR domain protein PTCD2 was shown to regulate plants, where they constitute a large family of mitochondrial small ribosomal subunit and is important for protein synthesis (20). The functions of the remaining PPR domain proteins in mammalian mitochondria have not been elucidated to date.

Here we have investigated the role of the previously uncharacterized mammalian PTCD1 and show that it associates with and regulates the level of leucine tRNAs in mitochondria. We show that by decreasing PTCD1 we increase leucine tRNA levels in cells and consequently observe an increased expression of mitochondrial-encoded Complex I and IV subunits and increased Complex IV activity.

MATERIALS AND METHODS

Plasmid expression vectors

All expression vectors were based on pcDNA3 (Invitrogen). Full-length human PTCD1 (NCBI accession number NP_056360) was expressed with its native termination codon or fused to a tandem affinity purification tag (TAP, ABO76910) (21) or EYFP (BD Biosciences) at the C-terminus. All plasmids were tested for expression by transfection and immunoblotting.

Cell culture

143B osteosarcoma cells were cultured at 37°C under humidified 95% air/5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen) containing glucose (4.5 g·l−1), 1 mM pyruvate, 2 mM glutamine, penicillin (100 U·ml−1), streptomycin sulphate (100 µg·ml−1) and 10% fetal bovine serum (FBS). Rho0 143B cybrids were a gift from Dr Elizabeth Ledgerwood, University of Otago, New Zealand and MELAS A3243G 143B cybrids were a gift from Prof. Rudolf Wiesner, University of Köln, Germany, with permission from Dr Eric Shoubridge. These were grown in the same medium supplemented with uridine (50 µg·ml−1).

Mitochondrial isolation and subfractionation

Mitochondria were prepared from 107 cells grown overnight in 15 cm2 dishes and isolated as described before (22). Rat liver mitochondria were prepared by homogenization in 250 mM sucrose, 5 mM Tris–HCl pH 7.4 and 1 mM EGTA (STE) followed by differential centrifugation (23) and the protein concentration determined by the biuret assay using BSA as a standard (24). Rat liver mitochondria were washed and suspended in STE containing 0.1% (w/v) fat-free BSA (STE/BSA) instead of STE for the final spin. The final pellet was suspended in a minimal amount of STE/BSA and the protein concentration was measured by the biuret assay.

The mitochondria were diluted with STE/BSA to a final concentration of 100 mg·ml−1 and stirred on ice. One millitre of digitonin (12.5 mg·ml−1) was added dropwise over 2 min and the solution was kept on ice for a further 15 min. Three volumes of STE/BSA were added and the mixture was homogenized four times with a tight homogenizer. The mitoplasts were collected by centrifugation for 10 min at 10 000g and the concentration was measured using the biuret assay. The supernatant was kept and centrifuged at 144 000g for 20 min at 5°C to separate the intermembrane fraction (supernatant) from the outer membrane (pellet). The mitoplasts were suspended at 30 mg·ml−1 in STE containing 0.16 mg lubrol mg−1 mitoplast protein and incubated on ice for 20 min. This solution was diluted with three volumes of STE and centrifuged at 144 000g for 50 min at 5°C to separate the matrix (supernatant) from the inner membrane (pellet). Both membrane fractions were suspended in 1% lauryl malside in STE. The protein concentration of each fraction was determined using the BCA assay (25) and immunoblotting was carried out to confirm the fractionation.

Transfections

143B cells were plated at 60% confluence in six-well plates or 10-cm dishes and transfected with annealed siRNAs or mammalian expression plasmids in OptiMEM media (Invitrogen). A total of 125 nM (for six-well plates) or 145 nM (for 10-cm dishes) of PTCD1 or control, off-target siRNAs (Dharmacon) were transfected using Lipofectamine 2000 (Invitrogen). A total of 158 ng·cm−2 of PTCD1 or control EYFP plasmid DNA was transfected using Fugene HD (Roche). Cell incubations were carried out for up to 72 h following transfection. PTCD1 expression was detected by immunoblotting using a polyclonal PTCD1 antibody.

Fluorescence cell microscopy

For immunocytochemistry, 143B cells were plated onto 13-mm diameter glass coverslips and allowed to attach overnight. Non-transfected cells were fixed with 4% paraformaldehyde in Tris buffered saline (TBS) for 30 min, washed with TBS and incubated with 10% FCS/0.1% Triton X-100/TBS (TBST) for 10 min. The PTCD1 antibody (1:500) diluted in TBST was added and incubated for 3 h at room temperature. After washing with TBS (3 × 5 min) the cells were incubated with antirabbit IgG Oregon green secondary antibody (diluted 1:100 in TBS) (Molecular Probes) for 15 min in the dark. Cells were then washed in TBS. Alternatively, cells were transfected with pPTCD1-EYFP for 48 h, and at the end of the incubation treated with 100 nM Mitotracker Orange for 15 min, then fixed with 4% paraformaldehyde in TBS for 30 min and washed with TBS. Cells were mounted in DABCO/PVA medium. Images were acquired using an Olympus DP70 fluorescent inverted microscope using a Nikon 40× objective.
Affinity purification and RNA isolation

143B cells were lysed in 50 mM Tris/HCl (pH 7.5), 125 mM NaCl, 5% glycerol, 1% Igepal CA-630, 1.5 mM MgCl₂, 1 mM DTT, 25 mM NaF, 1 mM Na₃VO₄, 1 mM EDTA, 1× complete protease inhibitors (Roche), 200 U ml⁻¹ RNaseOUT (Invitrogen) at 4°C. The lysate was cleared by centrifugation and incubated with rabbit-IgG agarose (Sigma) at 4°C for 2 h. The agarose was washed with lysis buffer and then with 10 mM Tris/HCl, pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 1% Igepal CA-630, 200 U ml⁻¹ RNaseOUT and protein was eluted by addition of 10 U of AcTEV protease (Invitrogen, RT for 1 h). RNA was isolated using the miRNeasy Mini kit (Qiagen) incorporating an on-column RNase-free DNase digestion to remove all DNA. For slot blotting, RNA was isolated from 5×10⁶ 143B cells expressing PTCD1-TAP or EYFP-TAP by affinity purification as described above. The entire sample of purified RNA was applied to a Hybond-N⁺ nitrocellulose membrane using a Bio-Dot SF microfiltration apparatus (BioRad) and probed as described for the northern blots.

Quantitative RT–PCR

The transcript abundance of mitochondrial genes and pre-processed junctions was measured on RNA isolated from 143B cells using the miRNeasy RNA extraction kit (Qiagen). Levels of PTCD1 mRNA were measured from RNA isolated from normal human tissues (Ambion). cDNA was prepared using ThermoScript reverse transcriptase (Invitrogen) and random hexamers and used as a template in the subsequent PCR that was performed using a Corbett Rotorgene 3000 using Platinum UDG SYBR Green mastermix (Invitrogen) and normalized to 18S ribosomal RNA. Primer sequences are listed in Supplementary Table 1.

Northern blotting

RNA (20 μg) was resolved on 1.2% agarose formaldehyde gels, then transferred to 0.45 μm Hybond-N⁺ nitrocellulose membrane (GE Lifesciences) and hybridized with biotinylated oligonucleotide probes specific to mitochondrial tRNAs (Supplementary Table 1). The hybridizations were carried out overnight at 50°C in 5× SSC, 20 mM Na₂HPO₄, 7% SDS and 100 μg ml⁻¹ heparin, followed by washing. The signal was detected using a streptavidin-linked horseradish peroxidase (diluted 1:2000 in 3× SSC, 5% SDS, 25 mM Na₂HPO₄, pH 7.5) by enhanced chemiluminescence (GE Lifesciences).

Immunoblotting

Specific proteins were detected using a mouse ND1 monoclonal antibody (diluted 1:2000, Santa Cruz Biotechnology), NDUFA9, COXI, COXII and COXIV (MitoSciences, diluted 1:2000), Bcl-2 antibody (Zymed, diluted 1:500) in 1% skim milk powder in phosphate-buffered saline (PBS). Control immunoblots against porin (MitoSciences, diluted 1:2000) were used to confirm normalized protein loading. Control immunoblots of the cytosol fractions against the MnSOD antibody showed complete separation of the mitochondria from the cytosol.

Respiration

Permeabilized cell respiration on glutamate/malate was measured according to Kuznetsov et al. (26). Briefly, 1×10⁶ cells were washed in PBS, resuspended in 0.25 ml mitomedium B (0.5 mM EGTA, 3 mM MgCl₂, 20 mM taurine, 10 mM KH₂PO₄, 20 mM HEPES, 1 g l⁻¹ fatty acid-free BSA, 60 mM lactobionate, 110 mM mannitol, 0.3 mM DTT, pH 7.1 with KOH) and added to 0.5 ml mitomedium B in a 1 ml Rank Brothers Oxygen Electrode thermostatically maintained at 37°C. The system was left to equilibrate for 5 min, before adding digitonin (50 μg ml⁻¹) and waiting for 5 min for the oxygen consumption to decline. Respiration of the permeabilized cells was initiated with 10 mM glutamate and 5 mM malate.

Complex enzyme assays

Enzyme assays were carried out in a 1 ml cuvette at 30°C using a Perkin Elmer lambda 35 dual beam spectrophotometer. For mitochondrial oxidative phosphorylation complex assays, mitochondria in STE plus protease inhibitors were disrupted by two to four cycles of freezing in dry ice/ethanol and thawing at 30°C. Combined Complex II to Complex III activity was assayed as the myxothiazol-sensitive rate of reduction of ferricytochrome c by succinate (27). Complex III was measured as the myxothiazol-sensitive rate of reduction of ferricytochrome c by CoQ2 and Complex IV was measured as the cyanide-sensitive oxidation of ferrocytochrome c (27).

RESULTS

PTCD1 is a mitochondrial matrix protein with eight PPR domains

The uncharacterized PPR-domain protein PTCD1 has been noted previously to share homology with the Neurospora crassa protein CIA84 that is an assembly factor for mitochondrial Complex I. However, the reciprocal best match of PTCD1 in N. crassa is the uncharacterized protein NCU007871 (Supplementary Figure 1) and the most distinctive features of PTCD1 are its eight PPR domains and an N-terminal mitochondrial targeting sequence (Figure 1A, Supplementary Figure 2).

We measured the mRNA levels of PTCD1 in human tissues and found that it is most abundant in testes, skeletal muscle and heart (Figure 1B). We fused the C-terminus of the protein to EYFP and showed that PTCD1 localizes specifically to mitochondria in 143B cells (Figure 1C). We used an antibody to PTCD1 to confirm its localization to mitochondria (Figure 1C). Fractionation of isolated mitochondria from rat liver into the four compartments, followed by immunoblotting of each fraction against a marker protein, indicated that...
PTCD1 was predominantly a mitochondrial matrix protein (Figure 1D).

PTCD1 associates with mitochondrial leucine tRNAs

We fused the C-terminus of PTCD1 to a TAP tag and expressed this protein in 143B osteosarcoma cells. We used the TAP tag to isolate the PTCD1-TAP protein from cells and measured the enrichment of the 13 mitochondrial RNA transcripts by quantitative reverse transcriptase PCR (QRT-PCR) to determine the RNA targets of PTCD1. There was no significant enrichment observed of these transcripts compared to the control EYFP-TAP protein (Figure 2A). Because many plant PPR domain proteins are involved in processing of organelle transcripts, we investigated if PTCD1 bound any of the mitochondrial precursor RNAs. We designed primers around the junctions between each gene and most of these areas included tRNAs which are thought to act as ‘punctuation marks’ for most of the mammalian mRNA transcripts. We found that two junction transcripts were enriched in RNA associated with the eluted PTCD1-TAP compared to purification from cells that express a control, EYFP-TAP protein. (A) Enriched mitochondrial mRNA transcripts compared to control. (B) Enrichment of mitochondrial RNA junction transcripts compared to control (n.d., not detected). (C) Enrichment of leucine tRNAs compared to control. Data are means ± SD of three separate experiments. (D) Enrichment of leucine tRNAs but not 12S rRNA, confirmed by slot blotting using biotinylated oligonucleotide probes.
tRNAs (tRNA^{Leu(UUR)} and tRNA^{Leu(CUN)}) were targets for PTCD1 (Figure 2C). To confirm that the association of PTCD1 with mitochondrial leucine tRNAs was specific, we isolated the enriched RNA from cells expressing PTCD1-TAP or EYFP-TAP and detected the presence of tRNA^{Leu(UUR)}, tRNA^{Leu(CUN)} and 12S rRNA by hybridization with biotinylated oligonucleotide probes against these transcripts. We found that tRNA^{Leu(UUR)} and tRNA^{Leu(CUN)} were specifically enriched in RNA associated with PTCD1-TAP but not in the control RNA isolated from cells expressing EYFP-TAP (Figure 2D).

PTCD1 lowers the abundance of mitochondrial leucine tRNAs

We investigated the effects of PTCD1 knockdown and overexpression in 143B cells. We used two distinct siRNA duplexes that significantly lowered the protein levels of PTCD1 but did not affect the abundance of porin, which was used as a loading control (Figure 3A). Next, we found that the mature mRNA and rRNA transcripts were not affected by knocking down or overexpressing PTCD1 in 143B cells (Figure 3B) suggesting that PTCD1 does not affect processing of the polycistronic mitochondrial mRNA in a way that changes the abundance of the mature mRNAs. We investigated the levels of mitochondrial mature transcripts by northern blotting and found that they were not changed when PTCD1 was knocked down or overexpressed (Figure 3C). Then we investigated the effect of PTCD1 knockdown and overexpression on the mitochondrial RNA junctions and found that increasing PTCD1 abundance reduced the precursor ND4–5 transcripts, whereas decreasing PTCD1 30 abundance resulted in an increase of the ND4–5 transcript (Figure 3D). RNA19 levels were not significantly affected with the changes in PTCD1 abundance. However, we observed that the levels of transcript junctions ND1–2, ND2-tRNA^{Ala} and COI-COII increase when PTCD1 is knocked down in cells (Figure 3D). Also, we observed that the level of these transcript junctions is decreased significantly when the levels of PTCD1 are increased (Figure 3D).

We investigated changes in mitochondrial tRNAs in cells where PTCD1 was knocked down or overexpressed by northern blotting. We observed a decrease of tRNA^{Leu(UUR)} and tRNA^{Leu(CUN)} when PTCD1 was overexpressed in cells either wild type or as a TAP fusion, respectively (Figure 4A and B). Knockdown of PTCD1 in cells led to increased accumulation of both leucine tRNAs using two distinct siRNA duplexes (Figure 4A and B). Changes in cellular PTCD1 levels did not affect the abundance of other tRNAs such as tRNA^{Gin}, tRNA^{Trp}, tRNA^{Ala} (Figure 4C–E), nor the levels of tRNA^{Ser(AGY)} and tRNA^{His} associated with the ND4–5 precursor transcript (Figure 4F–G).

PTCD1 knockdown leads to an increase in mitochondrial and nuclear-encoded subunits of Complexes I and IV

Changes in mitochondrial tRNA levels have been shown to affect the translation of mitochondrial-encoded genes (28). Therefore, we investigated, by immunoblotting, differences in mitochondrial-encoded proteins in 143B cells where PTCD1 was knocked down or overexpressed. We found increased protein levels of subunits I and II of Complex IV when PTCD1 was knocked down and decreased levels of these proteins when PTCD1 was overexpressed in the cells (Figure 5A). We observed the same trend with the ND1 subunit of Complex I (Figure 5B). In addition, there are possibly subtle changes in the levels of nuclear-encoded subunits subunit IV of Complex IV and NDUF9 of Complex I (Figure 5A and C). We used porin as a loading control to show that the mitochondrial protein abundance was equal under all treatment conditions (Figure 5A–C).

Functional effects of PTCD1 knockdown and overexpression

Because we observed changes in several subunits of Complexes I and IV, we measured if their activities were affected when PTCD1 was knocked down or overexpressed in 143B cells. The activity of Complex I measured by respiration of digitonin-permeabilized cells on glutamate/malate was not affected significantly when PTCD1 was knocked down in 143B cells (Figure 6A). However, enzyme assays showed an increased Complex IV activity when PTCD1 was knocked down in cells (Figure 6B). The enzyme activities of Complexes II to III and Complex III were unaffected by the changes in PTCD1 abundance (Figure 6C and D).

DISCUSSION

Here we show that PTCD1 is a mitochondrial matrix protein that is more abundant in mitochondria-rich tissues. Comparative genomic analyses have predicted PTCD1 to be an assembly factor for Complex I because of some shared homology with the N. crassa protein CIA84. Since PTCD1 is associated with both the mitochondrial matrix and the inner membrane, it could be considered that PTCD1 may have two functions within mitochondria, as an RNA-binding protein and a Complex I assembly factor. In this study we found that PTCD1 has an important role as an RNA regulator.

The eight predicted PPR domains most likely give PTCD1 RNA-binding affinity for the leucine tRNAs (tRNA^{Leu(CUN)} and tRNA^{Leu(UUR)}) and the precursor RNAs that contain them. This suggests that the binding of PTCD1 to the tRNAs does not require aminoacylation nor CCA addition at the 3' end of the tRNAs. Overexpression of PTCD1 reduced the levels of leucine tRNAs in cells, while siRNA knockdown of PTCD1 increased the levels of these tRNAs. In addition, we show that increasing the abundance of PTCD1 in cells decreases the levels of precursor ND4–5 RNA as a result of reduced tRNA^{Leu(CUN)} levels. The tRNA^{Leu(UUR)} levels have a more subtle decrease which is not apparent at the RNA19 level. Changing PTCD1 levels affected some other precursor RNAs; however, the levels of the tRNAs contained within these transcripts that we investigated were not changed. It is not clear if these represent genuine genes.
PTCD1 targets or whether these changes are a secondary effect of PTCD1 at the regions containing the leucine tRNAs which affects the rate or hierarchy of processing of primary mtDNA transcripts. Because altered levels of PTCD1 modulate the levels of leucine tRNAs without affecting the levels of the mRNAs that flank them, it seems unlikely that PTCD1 acts solely at the level of RNA processing. Whether PTCD1 induces cleavage of
the leucine tRNAs before or after RNase P and RNase Z cleavage remains to be determined. The observation that mRNA levels are not changed implies that either PTCD1 has an effect after tRNA processing or that mRNA processing can proceed even if the intervening tRNA is cleaved. This suggests a negative regulatory function of PTCD1 at the tRNA level that does not severely affect the processing and translation of mitochondrial transcripts. This contrasts with a recent study where mice lacking the PTCD2 gene showed an increase in a precursor RNA containing cytochrome b and a concomitant decrease in mature cytochrome b mRNA (19).

The enrichment of leucine tRNAs with PTCD1 from cells was detected using primers that bind only within the tRNAs, which are present at higher amounts than the precursor RNAs that contain them. Although a high-resolution structure of a PPR domain has not yet been described, structural modelling has led to the proposal that PPR domains most likely bind single-stranded RNA (29). Since tRNAs have mostly double-stranded structures, there could be two possible modes of association between PTCD1 and leucine tRNAs; PTCD1 could either bind sequences found in the loop regions of properly folded tRNA or it could bind in regions that are double stranded in the properly folded tRNA by associating before the tRNA has folded or by displacing the non-target strand to enable its association. The degradation of leucine tRNAs could result from nuclease activity of PTCD1; however, we could not identify any regions of primary sequence with similarity to known nuclease domains. Alternatively, PTCD1 may recruit
nucleases that cleave the leucine tRNAs or rearrange the tRNA structure to produce a substrate for a nuclease activity not directly associated with PTCD1. We have found that PTCD1 is insoluble when expressed in *Escherichia coli* and in wheat germ extract, which has made functional *in vitro* studies difficult. The ability to generate soluble recombinant PTCD1 will be critical for functional analysis of the RNA-binding affinities and minimal recognition sites. Towards this goal we are investigating the binding affinity of individual PTCD1 domains for the leucine tRNAs.

The targeted destruction of tRNAs has been observed in the cytoplasm of a variety of diverse organisms ranging from bacteria and plants to mammalian cells (30,31). To the best of our knowledge this phenomenon has been observed here in an organelle for the first time. The depletion of tRNA provides a rapid way to lower protein translation in response to cellular stresses such as oxidative stress, nutrient deprivation and amino acid starvation (31). Increased leucine tRNAs in response to PTCD1 knockdown increased mitochondrial-encoded Complexes I and IV subunits, suggesting that leucine tRNAs may be rate-limiting for mitochondrial protein synthesis. The subtle increases in nuclear-encoded subunits of Complexes I and IV are most likely a retrograde response to the increased mitochondria-encoded subunits. We have investigated the effects of PTCD1 overexpression and knockdown on *de novo* mitochondrial protein synthesis in 143B cells and found that there were subtle but not significant differences in the abundance of the 13 mitochondria-encoded proteins (Supplementary Figure 5). The subtle protein changes over 1 h of *de novo* synthesis may accumulate over time to yield significant differences in the steady state levels of the proteins after knockdown or overexpression of PTCD1, as detected by immunoblotting. This is consistent with the observed functional increase in the activity of Complex IV following PTCD1 knockdown. We have observed that cybrids devoid of mitochondrial DNA or cybrids with a mutation in the tRNA<sup>Leu(UUR)</sup> that causes MELAS, have increased levels of PTCD1 (Supplementary Figure 7). Although the physiological inducers of PTCD1 remain to be identified, this suggests that PTCD1 may play a role in the regulation of mitochondrial gene expression in response to stress.

In mammals mitochondrial transcripts lack introns and untranslated regions and rely on tRNA processing to generate mature RNAs, whereas in yeast mitochondrial transcripts have 5′ untranslated regions that regulate translation and plant mitochondrial transcripts are edited and have introns. The diverse regulatory functions of PPR proteins may have evolved in different organisms as a result of the idiosyncratic features of organelle gene expression between different kingdoms. Mammalian PPR domain proteins studied to date regulate mitochondrial gene expression by different mechanisms: POLRMT transcribes mtDNA (5), PTCD2 processes specific precursor RNAs (19), LRPPRC stabilizes specific mRNAs (14), PTCD3 associates with the small ribosomal subunit and is necessary for efficient translation (20) and MRPP3 is a subunit of the RNase P complex needed for processing of tRNAs (16). We have expanded the repertoire of PPR protein function by showing that PTCD1 acts as a negative regulator of specific mitochondrial tRNAs. Further characterization of mammalian PPR domain proteins will provide insights into the regulation of mitochondrial gene expression at a post-transcriptional level.

**SUPPLEMENTARY DATA**

Supplementary Data are available at NAR Online.

**ACKNOWLEDGEMENTS**

The authors thank A/Prof. Michael Ryan from La Trobe University for the PTCD1 antibody and Prof. Ian Small from UWA for critical discussion and advice.

**FUNDING**

National Health and Medical Research Council. Funding for open access charge: Royal Perth Hospital Medical Research Foundation.

Conflict of interest statement. None declared.

**REFERENCES**

1. Smeitink,J., van den Heuvel,L. and DiMauro,S. (2001) The genetics and pathology of oxidative phosphorylation. *Nat. Rev. Genet.*, 2, 342–352.
2. Shoubridge,E.A. (2001) Nuclear genetic defects of oxidative phosphorylation. *Hum. Mol. Genet.*, 10, 2277–2284.
3. DiMauro,S. and Schon,E.A. (2003) Mitochondrial respiratory-chain diseases. *N. Engl. J. Med.*, 348, 2656–2668.
4. Taylor,R.W. and Turnbull,D.M. (2005) Mitochondrial DNA mutations in human disease. *Nat. Rev. Genet.*, 6, 389–402.
5. Falkenberg,M., Larsson,N.G. and Gustafsson,C.M. (2007) DNA replication and transcription in mammalian mitochondria. *Annu. Rev. Biochem.*, 76, 679–699.
6. Gagliardi,D., Stepen,P.P., Temperley,R.J., Lightowlers,R.N. and Chrzanowska-Lightowlers,Z.M. (2004) Messenger RNA stability in mitochondria: different means to an end. *Trends Genet.*, 20, 260–267.
7. Anisimov,S.V. (2005) A large-scale screening of the normalized mammalian mitochondrial gene expression profiles. *Genet. Res.*, 86, 127–138.
8. Connor,M.K., Takahashi,M. and Hood,D.A. (1996) Tissue-specific stability of nuclear- and mitochondrially encoded mRNAs. *Arch. Biochem. Biophys.*, 333, 103–108.
9. Ostromoff,L.K., Izquierdo,J.M., Enriquez,J.A., Montoya,J. and Cuevza,J.M. (1996) Transient activation of mitochondrial translation regulates the expression of the mitochondrial genome during mammalian mitochondrial differentiation. *Biochem. J.*, 316(Pt 1), 183–191.
10. Ojala,D., Montoya,J. and Attardi,G. (1981) tRNA punctuation model of RNA processing in human mitochondria. *Nature*, 290, 470–474.
11. Nagaike,T., Suzuki,T., Katoh,T. and Ueda,T. (2005) Human mitochondrial mRNAs are stabilized with polyadenylation regulated by mitochondria-specific poly(A) polymerase and polynucleotide phosphorylase. *J. Biol. Chem.*, 280, 19721–19727.
12. Sharma,M.R., Koc,E.C., Datta,P.P., Booth,T.M., Spremulli,L.L. and Agrawal,R.K. (2003) Structure of the mammalian mitochondrial ribosome reveals an expanded functional role for its component proteins. *Cell*, 115, 97–108.
13. Mili,S. and Pinol-Roma,S. (2003) LRPP130, a pentatricopeptide motif protein with a noncanonical RNA-binding domain, is bound...
in vivo to mitochondrial and nuclear RNAs. Mol. Cell Biol., 23, 4972–4982.
14. Xu,F., Morin,C., Mitchell,G., Ackerley,C. and Robinson,B.H. (2004) The role of the LRPPRC (leucine-rich pentatricopeptide repeat cassette) gene in cytochrome oxidase assembly: mutation causes lowered levels of COX (cytochrome c oxidase) I and COX II mRNA. Biochem. J., 382, 331–336.
15. Mootha,V.K., Lepage,P., Miller,K., Bunkenborg,J., Reich,M., Hjerrild,M., Delmonte,T., Villeneuve,A., Sladek,R., Xu,F. et al. (2003) Identification of a gene causing human cytochrome oxidase deficiency by integrative genomics. Proc. Natl Acad. Sci. USA, 100, 605–610.
16. Holzmann,J., Frank,P., Loffler,E., Bennett,K.L., Gerner,C. and Rossmanith,W. (2008) RNase P without RNA: Identification and functional reconstitution of the human mitochondrial tRNA processing enzyme. Cell, 135, 462–474.
17. Lightowlers,R.N. and Chrzanowska-Lightowlers,Z.M. (2008) PPR (pentatricopeptide repeat) proteins in mammals: important aids to mitochondrial gene expression. Biochem. J., 416, e5–e6.
18. Schmitz-Linneweber,C. and Small,I. (2008) Pentatricopeptide repeat proteins: a socket set for organelle gene expression. Trends Plant Sci., 13, 663–670.
19. Xu,F., Ackerley,C., Maj,M.C., Addis,J.B., Levandovskiy,V., Lee,J., Mackay,N., Cameron,J.M. and Robinson,B.H. (2008) Disruption of a mitochondrial RNA-binding protein gene results in decreased cytochrome b expression and a marked reduction in ubiquinol-cytochrome c reductase activity in mouse heart mitochondria. Biochem. J., 416, 15–26.
20. Davies,S.M.K., Rackham,O., Shearwood,A.-M.J., Hamilton,K.L., Narsai,R., Whelan,J. and Filipovska,A. (2009) Pentatricopeptide repeat domain protein 3 associates with the mitochondrial small ribosomal subunit and regulates translation. FEBS Lett., 583, 1853–1858.
21. Burckstummer,T., Bennett,K.L., Preradovic,A., Schutze,G., Hantschel,O., Superti-Furga,G. and Bauch,A. (2006) An efficient tandem affinity purification procedure for interaction proteomics in mammalian cells. Nat. Methods, 3, 1013–1019.
22. Rackham,O., Nichols,S.J., Leedham,P.J., Berners-Price,S.J. and Filipovska,A. (2007) A gold(I) phosphate complex selectively induces apoptosis in breast cancer cells: Implications for anticancer therapeutics targeted to mitochondria. Biochem. Pharmacol., 74, 992–1002.
23. Chappell,J.B. and Hansford,R.G. (1972) In Birnie,G.D. (ed.), Subcellular Components: Preparation and Fractionation., Butterworths, London, pp. 77–91.
24. Gornall,A.G., Bardwills,C.J. and David,M.M. (1949) Determination of serum protein by means of the biuret reaction. J. Biol. Chem., 177, 751–766.
25. Smith,P.K., Krohn,R.L., Hermanson,G.T., Mallia,A.K., Gartner,F.H., Provenzano,M.D., Fujimoto,E.K., Geoke,N.M., Olson,B.J. and Klenk,D.C. (1985) Measurement of protein using bicinchoninic acid. Anal. Biochem., 150, 76–85.
26. Kuznetsov,A.V., Veksler,V., Gellerich,F.N., Saks,V., Margreiter,R. and Kunz,W.S. (2008) Analysis of mitochondrial function in situ in permeabilized muscle fibers, tissues and cells. Nat. Protoc., 3, 965–976.
27. James,A.M., Wei,Y.-H., Pang,C.-Y. and Murphy,M.P. (1996) Altered mitochondrial function in fibroblasts containing MELAS or MERRF mitochondrial DNA mutations. Biochem. J., 318, 401–407.
28. Hayashi,J., Ohta,S., Kagawa,Y., Takai,D., Miyabayashi,S., Tada,K., Fukushima,H., Inui,K., Okada,S., Goto,Y. et al. (1994) Functional and morphological abnormalities of mitochondria in human cells containing mitochondrial DNA with pathogenic point mutations in tRNA genes. J. Biol. Chem., 269, 19060–19066.
29. Delannoy,E., Bradley,J., Bond,C.S. and Small,I.D. (2007) Pentatricopeptide repeat (PPR) proteins as sequence-specificity factors in post-transcriptional processes in organelles. Biochem. Soc. Trans., 35, 1643–1647.
30. Haiser,H.J., Karginov,F.V., Hannon,G.J. and Elliot,M.A. (2008) Developmentally regulated cleavage of tRNAs in the bacterium Streptomyces coelicolor. Nucleic Acids Res., 36, 732–741.
31. Thompson,D.M., Lu,C., Green,P.J. and Parker,R. (2008) tRNA cleavage is a conserved response to oxidative stress in eukaryotes. RNA, 14, 2095–2103.